title: Pharmacogenetic considerations in the treatment of gout.
abstract: Gout is one of the most common forms of arthritis and the prevalence is increasing. Management comprises rapid and effective control of the inflammation in acute gout and sustained urate lowering in the long term. Improving the outcomes for cheaper old drugs and for the increasing number of new, more expensive agents is an important clinical goal. The role of pharmacogenetics in predicting response and adverse events to gout therapies is of considerable interest. Currently, prospective screening is employed to detect HLA-B*5801 carriage and glucose-6-phosphate dehydrogenase deficiency, to minimize occurrence of allopurinol hypersensitivity and pegloticase-related hemolytic anemia. In the future it is likely that other genetic markers of drug response will make the transition to clinical practice to further improve the efficacy and safety of gout therapies. In this review, we will examine the potential clinical relevance of specific genetic variants in the management of gout.
authors: Department of Surgical Sciences, Dunedin School of Medicine, Dunedin, New Zealand.
authors: Rebecca L
authors: RL
authors: Roberts
authors: Lisa K
authors: LK
authors: Stamp
mesh_terms: D000493:Allopurinol / Q000097:blood / Q000627:therapeutic use; D006073:Gout / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood
chemical_list: D015235:HLA-B Antigens; C500126:HLA-B*58:01 antigen; D014527:Uric Acid; D000493:Allopurinol
keywords: CYP2C9; HLA-B*5801; NSAIDs; allopurinol; benzbromarone; glucose-6-phosphate deficiency; gout; pegloticase; pharmacogenetics; uric acid transporters